“Agreement Between Time-Domain and Spectral-Domain Optical Coherence Tomography in the Assessment of Macular Thickness in Patients with Idiopathic Macular Telangiectasia Type 2”, Ophthalmologica, vol. 230, pp. 144-150, 2013.
, “Associations Between Autofluorescence Abnormalities and Visual Acuity in Idiopathic Macular Telangiectasia Type 2: MacTel Project Report Number 5”, Retina, vol. 34, pp. 1630-1636, 2014.
, “Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2”, Ophthalmic Epidemiol, vol. 17, pp. 66-73, 2010.
, “Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial”, Am J Ophthalmol, vol. 159, pp. 659-666.e1., 2015.
, “"En Face" OCT Imaging of the IS/OS Junction Line in Type 2 Idiopathic Macular Telangiectasia”, Invest Ophthalmol Vis Sci, vol. 53, pp. 6145-6152, 2012.
, “Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2”, PLoS One, vol. 7, p. e24268, 2012.
, “The IS/OS Junction Layer in the Natural History of Type 2 Idiopathic Macular Telangiectasia”, Invest Ophthalmol Vis Sci, vol. 53, pp. 7889-7895, 2012.
, “Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3”, Ophthalmic Epidemiol, vol. 20, pp. 109-113, 2013.
, “Multimodal Imaging in Type 2 Idiopathic Macular Telangiectasia”, Retina, vol. 35, pp. 742-749, 2015.
, “The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project”, Invest Ophthalmol Vis Sci, vol. 49, pp. 4340-4346, 2008.
, “Progression of Vision Loss in Macular Telangiectasia Type 2”, Invest Ophthalmol Vis Sci, vol. 56, pp. 3905-3912, 2015.
, “Retinal Crystals in Type 2 Idiopathic Macular Telangiectasia”, Opthalmology, vol. 118, pp. 2461-2467, 2011.
,